Odyssey Health, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph Michael Redmond
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2300 West Sahara Avenue Las Vegas NV United States of America 89102
- IPO Date
- Jan 8, 2021
- CIK
- 0001626644
- Website
- odysseyhealthinc.com
- Similar Companies
- Business
- Odyssey Health, Inc. operates as a medical technology enterprise, concentrating on the advancement of distinctive health solutions. The company is actively developing CardioMap, a non-invasive monitoring and screening device for cardiac health, alongside the Save A Life choking rescue mechanism. Through its subsidiary, Odyssey recently acquired exclusive worldwide sub-licensing rights for BreastCheck®, an innovative at-home screening test for breast abnormalities. Headquartered in Las Vegas, Nevada, the firm, previously known as Odyssey Group International, Inc., commenced operations in 2014.
Odyssey Health, Inc. Secures Exclusive Global Distribution Rights for BreastCheck™ to Drive Recurring Revenue Growth
Odyssey Health, Inc. (OTCMKTS:ODYY) Short Interest Update
Odyssey Health, Inc. Secures Multi-Million-Dollar, Nine-Year Service Contract and Financing Facility for Up to $25 Million
Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace
Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device
Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.
Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders
Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.
Odyssey Health Inc. Begins Trading on the OTCQB
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
Odyssey Group International Approved to Start Human Trial to Treat Concussion
Odyssey Group International Completes IND-enabling Studies, Submits Investigator's Brochure for Phase 1 Clinical Trial
Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders
Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion
Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug
Odyssey Group International, Inc. Schedules Annual Meeting of Stockholders